Octreotide therapy for chylothorax in infants and children: A brief review

Pediatric Critical Care Medicine

Volumn 7, Issue 6, 2006, Pages 576-579

  Helin, Radley D ^a   Angeles, Sheila Therese V ^a   Bhat, Rama ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Chylothorax; Octreotide

Indexed keywords

OCTREOTIDE; SOMATOSTATIN;

ARTIFICIAL VENTILATION; CHYLOTHORAX; DIET THERAPY; EXPERIENCE; HUMAN; MEDLINE; PARENTERAL NUTRITION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SUPPLEMENTATION;

ANTINEOPLASTIC AGENTS, HORMONAL; CHILD; CHYLOTHORAX; HUMANS; INFANT; INFANT, NEWBORN; OCTREOTIDE;

EID: 33750811323     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PCC.0000235256.00265.C8     Document Type: Review

References (50)

1. Chernick V, Reed MH: Pneumothorax and chylothorax in the neonatal period. J Pediatr 1970; 76:624-632
2. Al-Zubairy SA, Al-Jazairi AS: Octreotide as a therapeutic option for management of chylothorax. Ann Pharmacother 2003; 37:679-682
3. Goens MB, Campbell D, Wiggins JW: Spontaneous chylothorax in Noonan syndrome. Am J Dis Child 1992; 146:1453-1456
4. Hamada H, Fujita K, Kubo T, et al: Congenital chylothorax in a trisomy 21 newborn. Arch Gynecol Obstet 1992; 252:55-58
5. Holzgreve W, HolzGreve B, Curry BJR: Non-immune hydrops fetalis: Diagnosis and management. Semin Perinatol 9:52-67
6. Al-Tawil K, Ahmed G, Al-Hathal M, et al: Congenital chylothorax. Am J Perinatol 2000; 17:121-126
7. Jacquemont S, Barbarot S, Boceno M: Familial congenital pulmonary lymphangectasia, non-immune hydrops fetalis, facial and lower limb lymphedema: Confirmation of Njolstad's report. Am J Med Genet 2000; 93:264-268
8. Nakamura Y, Komatsu Y, Yano H, et al: Non-immunologic hydrops fetalis: a clinicopathological study of 50 autopsy cases. Pediatr Pathol 1987; 7:19-30
9. Kessel I, Makhoul I, Sujov P: Congenital hypothyroidism and nonimmune hydrops fetalis: Associated? Pediatrics 1999; 103:e9-e11
10. Zito L, Keszler M: Massive edema and bilateral pleural effusions in a newborn infant. Ann Allergy 1989; 63:277-280
11. Merrigan BA, Winter DC, O'Sullivan GC: Chylothorax. Br J Surg 1997; 84:15-20
12. Beghetti M, La Scala G, Belli D, et al: Etiology and management of pediatric chylothorax. J Pediatr 2000; 136:653-658
13. van Straaten HLM, Gerards LJ, Krediet TG: Chylothorax in the neonatal period. Eur J Pediatr 1993; 152:2-5
14. Wasmuth-Pietzuch A, Hansmann M, Bartmann P, et al: Congenital chylothorax: Lymphopenia and high risk of neonatal infections. Acta Paediatr 2004; 93:220-224
15. Brodman RF: Congenital chylothorax: Recommendations for treatment. N Y State J Med 1975; 75:553-557
16. Vain NE, Swarner OW, Cha CC: Neonatal chylothorax: A report and discussion of nine consecutive cases. J Pediatric Surg 1980; 15:261-264
17. Demos NJ, Kozel J, Scerbo JE: Somatostatin in the treatment of chylothorax. Chest 2001; 119:964-966
18. Gonen R, Degani S, Kugelman A, et al: Intrapartum drainage of fetal pleural effusion. Prenat Diagn 1999; 19:1124-1126
19. Picone O, Benachi A, Mandelbrot L, et al: Thoracoamniotic shunting for fetal pleural effusions with hydrops. Am J Obstet Gynecol 2004; 191:2047-2050
20. Jorgensen C, Brocks V, Bang J: Treatment of severe fetal chylothorax associated with pronounced hydrops with intrapleural injection of OK-432. Ultrasound Obstet Gynecol 2003; 21:66-69
21. Tsukihara A, Tanemura M, Suzuki Y: Reduction of pleural effusion by OK-432 in a fetus complicated with congenital hydrothorax. Fetal Diagn Ther 2004; 19:327-331
22. Booth P, Nicolaides KH, Greenough A, et al: Pleuro-amniotic shunting for fetal chylothorax. Early Hum Dev 1987; 15:365-367
23. Dumont AE, Mayer DJ, Mulholland JH: The suppression of immunologic activity by diversion of thoracic duct lymph. Ann Surg 1964; 160:373-383
24. Servelle M, Nogues CI, Soulie J, et al: Spontaneous, postoperative and traumatic chylothorax. J Cardiovasc Surg 1980; 21:475-486
25. Lam JC, Aters S, Tobias JD: Initial experience with octreotide in the pediatric population. Am J Therapeutics 2001; 8:409-415
26. Bac DJ, Van Hagen PM, Postema PTE, et al: Octreotide for protein-losing enteropathy with intestinal lymphangiectasia. Lancet 1995; 345:1639
27. Cheung Y, Leung M, Yip M: Octreotide for treatment of postoperative chylothorax. J Pediatr 2001; 139:157-159
28. Goyal A, Smith NP, Jesudason EC, et al: Octreotide for treatment of postoperative chylothorax after repair of congenital diaphragmatic hernia. J Pediatr Surg 2003; 38:1-2
29. Nakabayashi H, Sagara H, Usukura N, et al: Effect of somatostatin on the flow rate and triglyceride levels of thoracic duct lymph in normal and vagotomized dogs. Diabetes 1981; 30:440-445
30. Ulibarri JI, Sanz Y, Fuentes C et al: Reduction of lymphorrhagia from ruptured thoracic duct by somatostatin. Lancet 1990; 2:258
31. Pratap U, Slavik Z, Ofoe VD, et al: Octreotide to treat postoperative chylothorax after cardiac operations in children. Ann Thorac Surg 2001; 72:1740-1742
32. Chanson P, Tamsit J, Harris AG: Clinical pharmacokinetics of octreotide: Therapeutic applications in patients with pituitary tumors. Clin Pharmacokinet 1993; 25:375-391
33. Goto M, Kawamata K, Kitano M, et al: Treatment of chylothorax in a premature infant using somatostatin. J Perinatol 2003; 23:563-564
34. Sivasli E, Dogru D, Aslan AT, et al: Spontaneous neonatal chylothorax treated with octreotide in Turkey: A case report. J Perinatol 2004; 24:261-262
35. Rimensberger P, Muller-Shenker B, Kalangos A, et al: Treatment of a persistent postoperative chylothorax with somatostatin. Ann Thorac Surg 1998; 66:253-254
36. Rasiah S, Oei J, Lui K: Octreotide in the treatment of congenital chylothorax. J Paediatr Child Health 2004; 40:585-588
37. Coulter D: Successful treatment with octreotide of spontaneous chylothorax in a premature infant. J Perinatol 2004; 24:194-195
38. Tibballs J, Soto R, Bharucha T, et al: Management of newborn lymphangectasia and chylothorax after cardiac surgery with octreotide infusion. Ann Thoracic Surg 2004; 77:2213-2215
39. Maayan-Metzger A, Sack J, Mazkereth R, et al: Somatostatin treatment of congenital chylothorax may induce transient hypothyroidism in newborns. Acta Paediatrica 2005; 94:785-789
40. Deleted in proof
41. Lam JC, Aters S, Tobias JD: Initial experience with octreotide in the pediatric population. Am J Therapeutics 2001; 8:409-415
42. Mohseni-Bod H, Macrae D, Slavik Z: Somatostatin analog (octreotide) in management of neonatal postoperative chylothorax: Is it safe? Pediatr Crit Care Med 2004; 5:356-357
43. Mikroulis D, Didilis V, Bitzikas G, et al: Octreotide in the treatment of chylothorax. Chest 2002; 121:2079-2080
44. Au M, Weber TR, Fleming RE: Successful use of somatostatin in a case of neonatal chylothorax. J Pediatr Surg 38:1106-1107
45. Hamdan M, Gaeta M: Octreotide and low-fat breast milk in postoperative chylothrorax. Ann Thorac Surg 2004; 77:2215-2217
46. Young S, Dalgleish S, Eccleston A, et al: Severe congenital chylothorax treated with octreotide. J Perinatol 2004; 200-202
47. Ottinger JG: Octreotide for persistent chylothorax in a pediatric patient. Ann Pharmacother 2002; 36:1106-1107
48. Rosti L, Bini R, Chessa M, et al: The effectiveness of octreotide in the treatment of post-operative chylothorax. Eur J Pediatr 2002; 161:149-150
49. Leelahanon S, Petlek W, Sontimuang W, et al: Can octreotide be the first line treatment for chylothorax? J Med Assoc Thai 2003; 86(Suppl 3):S741-S745
50. Siu S, Lam D: Spontaneous neonatal chylothorax treated with octreotide. J Paediatr Child Health 2006;42:65-67